INKT MiNK Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1840229 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY10.8%
TTM EPS YoY25.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-95.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets297.2%
Debt / equity—
Current ratio0.97x
Interest coverage317.82x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-33.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $200,000 | — | — | — | $0 | — | — | — |
| R&D expense | $1.80M | $1.89M | $1.20M | $1.51M | $1.14M | $1.84M | $1.26M | $1.41M |
| SG&A expense | $1.03M | $1.33M | $1.68M | $1.76M | $1.85M | $1.85M | $1.27M | $808,904 |
| Operating income | -$2.64M | -$3.22M | -$2.88M | -$2.71M | -$3.18M | -$4.05M | -$2.70M | -$2.50M |
| Interest expense | -$1,000 | -$2,000 | -$4,000 | -$29,000 | -$25,000 | -$27,000 | -$29,000 | -$30,000 |
| Net income | -$2.55M | -$3.13M | -$2.74M | -$2.60M | -$2.89M | -$4.24M | -$2.77M | -$2.46M |
| EBITDA | -$2.60M | -$3.18M | -$2.85M | -$2.67M | -$3.14M | -$4.00M | -$2.65M | -$2.45M |
| EPS (basic) | -0.50 | -0.62 | -0.57 | — | -0.65 | -1.06 | -0.70 | — |
| EPS (diluted) | -0.50 | -0.62 | -0.57 | — | -0.65 | -1.06 | -0.70 | — |
| Weighted avg. shares (diluted) | 5.10M | 5.02M | 4.80M | — | 4.44M | 3.98M | 3.96M | — |
| Banking | ||||||||
| Net interest income | $72,323 | $72,884 | $80,834 | $111,230 | $55,151 | $348 | $13,517 | $39,573 |
| Balance sheet | ||||||||
| Cash & equivalents | $7.47M | $8.81M | $9.53M | $13.36M | $14.28M | $1.68M | $3.23M | $4.58M |
| Current assets | $7.90M | $9.30M | $10.02M | $13.85M | $14.53M | $2.01M | $3.58M | $4.99M |
| PP&E, net | $339,160 | $318,474 | $354,518 | $390,869 | $429,344 | $473,215 | $687,500 | $732,929 |
| Total assets | $8.24M | $9.62M | $10.38M | $14.24M | $14.96M | $2.48M | $4.27M | $5.72M |
| Current liabilities | $8.18M | $7.57M | $7.29M | $13.03M | $13.43M | $13.16M | $12.12M | $6.96M |
| Total liabilities | $24.49M | $23.64M | $23.06M | $28.47M | $28.48M | $27.67M | $26.06M | $25.31M |
| Shareholders' equity | -$16.25M | -$14.03M | -$12.69M | -$14.23M | -$13.51M | -$25.19M | -$21.79M | -$19.59M |
| Shares outstanding | 5.10M | 5.10M | — | 4.71M | — | — | — | 3.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.28M | -$2.08M | -$1.73M | -$2.07M | -$941,348 | -$1.57M | -$1.34M | -$1.73M |
| Financing cash flow | $0 | $1.37M | -$2.10M | $1.18M | $13.55M | $540 | $576 | -$3 |
| Depreciation & amortization | $36,065 | $36,064 | $36,066 | $38,563 | $43,654 | $48,763 | $50,765 | $53,869 |
| Stock-based compensation | $333,000 | $422,000 | $630,386 | $565,771 | $621,000 | $897,000 | $591,089 | $390,048 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.